<DOC>
	<DOCNO>NCT01416116</DOCNO>
	<brief_summary>The Summary product characteristic ( SmPC ) QUTENZA advise topical anaesthetic apply prior application QUTENZA . This multi-center , randomize , assessor-blinded study investigate use oral analgesic alternative form pre-treatment QUTENZA .</brief_summary>
	<brief_title>Method Pre-treatment Application QUTENZA Capsaicin 8 % Patch</brief_title>
	<detailed_description>All patient treat QUTENZA 60 minute . Patients randomize one two arms- application topical anaesthetic ( lidocaine cream ) oral analgesic ( tramadol oral table ) prior application QUTENZA . Patients follow 7 day monitor pain score tolerability .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Peripheral Nerve Injuries</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Diagnosis postherpetic neuralgia neuropathic pain due peripheral nerve injury Daily pain score â‰¥ 4 average pain Screening Visit Treatment Visit Intact , nonirritated , dry skin painful area ( ) treat Significant ongoing recurrent pain due PHN peripheral nerve injury Past current history Type I Type II diabetes mellitus Active malignancy treatment malignancy within year prior Treatment Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>QUTENZA</keyword>
	<keyword>Pre-treatment</keyword>
	<keyword>Tramadol</keyword>
	<keyword>Tolerability</keyword>
</DOC>